ColoSense
Geneoscopy, Inc. · Decision date Aug 27, 2026
What did the FDA approve?
FDA records P230001/S012 as a supplement to PMA P230001, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Aug 27, 2026.
FDA approval order statement
ColoSense is intended for the qualitative detection of colorectal neoplasia associated RNA markers and for the presence of occult hemoglobin in human stool. ColoSense is a single-site test performed at Geneoscopy, Inc. A positive ColoSense result may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA), or serrated precancerous lesions (SPL) and should be followed by a colonoscopy. ColoSense is indicated as a screening test for adults, 45 years of age or older, who are at typical average-risk for developing CRC. ColoSense is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Pathology
- Decision date
- Aug 27, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P230001/S012
- Regulatory pathway
- PMA supplement
- Applicant
- Geneoscopy, Inc.
- Product code
- SBB
- Decision code
- APPR
- Decision date
- Aug 27, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, Colorectal Neoplasia, RNA Markers and Hemoglobin detection.
- Applicant
- Geneoscopy, Inc.
- Product code
- SBB
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230001. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230001 · Original PMA
ColoSense
P230001/S010 · Related supplement
ColoSense
P230001/S009 · Related supplement
ColoSense
P230001/S011 · Related supplement
ColoSense
P230001/S012 received
Application receipt date recorded by FDA.
P230001/S012 · FDA decision
Normal 180 Day Track
P230001/S014 · Related supplement
ColoSense
Timeline entries are records held by MedtechLedger for P230001. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230001
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ColoSenseP230001 | Geneoscopy, Inc. | PMA approval | May 3, 2024 | FDA |
ColoSenseP230001/S010 | Geneoscopy, Inc. | PMA supplement | Aug 14, 2025 | FDA |
ColoSenseP230001/S009 | Geneoscopy, Inc. | PMA supplement | Sep 15, 2025 | FDA |
ColoSenseP230001/S011 | Geneoscopy, Inc. | PMA supplement | Oct 24, 2025 | FDA |
ColoSenseP230001/S014 | Geneoscopy, Inc. | PMA supplement | Sep 8, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Geneoscopy, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2220 Welsch Industrial Ct., St. Louis, MO, 63146
Sources and methodology
- Original FDA record: P230001/S012
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


